Vilacto Bio Inc (OTCMKTS: VIBI) has been seeing lots of action in recent days as Investors continue to bid this one up. The stock has been getting more attention since the Company released a 10Q on February 19. The Company does have $127k in the treasury and reported some tiny revenues.
Microcapdaily initially covered VIBI last year when the stock began to trade more volume and get noticed. We noted at the time; “The Company was originally incorporated under the laws of the state of Nevada on February 25, 2013 as Zlato Inc., in April 2017, the Company changed their name to Vilacto Bio Inc. Currently the stock looks to be under promotion.”
Vilacto Bio Inc is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. The Company aims to further develop the Lactoactive® molecule for the purpose of increasing the quality of retail and medical skin cream products as well as licensing Lactoactive® molecule for the pharmaceutical industry.
The Company recently announced it has revealed the initial five areas of development for its new LACTOACTIVE iTHER® compound. These include a bio-injection that could be useful in preventing metastasis of malignant tumor cells in cancer treatment due to the hydrocolloid potent (HA). An inhaler spray to prevent recurrent upper respiratory tract infections (based on a 2016 study. A vaccine injection for nanoparticle antibody source for a vaccine producer or a new variant of gelatin capsules for patients with arthritis and other joint inflammation with fewer side effects – especially hypertension if people with diabetes – than Glucosamine.
LACTOACTIVE iTHER® is a new LACTOACTIVE variant that combines potent immune-system enhancement with a proven nanoparticle drug delivery system. These development programs are part of Vilacto Bio’s LACTOACTIVE iTHER® plan to form strategic partnerships with other biotech firms and become the “go-to” partner for enhancing new immunotherapy and vaccine solutions with its refined-colostrum compound “weaponized” as a nanomedicine.
VIBI CEO Gert Anderson stated “Our own research suggests, and we firmly believe, that LACTOACTIVE iTHER® can contribute significantly to emerging therapies for treating a number of diseases, including cancer, immunodeficiency disorders, osteoarthritis, psoriasis, thrombocytopenia and others.”
To Find out the inside Scoop on VIBI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
In November VIBI announced it has secured the patent applications for LACTOACTIVE® covering rights in the US, Canada Europe and Hong Kong. The transaction was finalized this November. Ownership of the patent applications, which Vilacto Bio had been licensing the US rights from a Danish company, is expected to give the company greater scope to continue developing the LACTOACTIVE® compound, and bolster its international IP ownership position.
The patent applications also cover the company’s new compound, LACTOACTIVE iTHER®, a LACTOACTIVE® variant that offers potent immune-system enhancement with a potential for treating a wide range of diseases. LACTOACTIVE iTHER® is expected to generate new revenue streams in addition to the company’s LACTOACTIVE®-based therapeutic skincare range..”
The main active component of LACTOACTIVE® and LACTOACTIVE iTHER® is colostrum, a natural substance that Vilacto Bio has refined and processed into a potent nanoparticle concentrate. In NPDDS form, the compound can be applied in deeper layers of the skin and, when injected, can penetrate cell walls to act directly on cytoplasm. The product is currently in the development stage and has not been approved for use by the FDA or any foreign agency.
We have a Monster Pick Coming. Subscribe Right Now!
Currently seeing another surge of volume VIBI has $127k in the treasury, rising debt and reported some tiny revenues last quarter. VIBI is an exciting Company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We will be updating on VIBI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with VIBI.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in VIBI either long or short and we have not been compensated for this article.